Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: A systematic review and meta-Analysis

Annals of the Rheumatic Diseases

Volumn 77, Issue 1, 2018, Pages 98-103

  Rempenault, Claire ^a   Combe, Bernard ^a   Barnetche, Thomas ^b   Gaujoux Viala, Cécile ^c   Lukas, Cédric ^a   Morel, Jacques ^a   Hua, Charlotte ^a  

^a UNIV MONTPELLIER   (France)

^b HÔPITAL PELLEGRIN   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ANTIRHEUMATIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; META ANALYSIS; METABOLIC DISORDER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; COMPLICATION; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; MORTALITY; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; HYDROXYCHLOROQUINE; METABOLIC DISEASES; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 85038254987     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2017-211836     Document Type: Article

References (42)

1. Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-Analysis. Joint Bone Spine 2013;80:29-33.
2. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-Analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
3. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17-28.
4. Wallace DJ. The history of antimalarials. Lupus 1996;5(1 suppl):2-3.
5. Wallace DJ, Gudsoorkar VS, Weisman MH, et al. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012;8:522-33.
6. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann Rheum Dis 2010;69:20-8.
7. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577-83.
8. Alarcón GS, McGwin G, Bertoli AM, et al. LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168-72.
9. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors?Arthritis Rheum 2006;54:3068-70.
10. Emami J, Gerstein HC, Pasutto FM, et al. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol 1999;77:118-23.
11. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993;23(2 Suppl 1):82-91.
12. Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 2012;42:145-53.
13. Emami J, Pasutto FM, Mercer JR, et al. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 1999;64:325-35.
14. Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999;26:195-6.
15. Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a nondiabetic patient treated for RA. Rheumatology 2008;47:378-9.
16. Gerstein HC, Thorpe KE, Taylor DW, et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-A randomized trial. Diabetes Res Clin Pract 2002;55:209-19.
17. Quatraro A, Consoli G, Magno M, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 1990;112:678-81.
18. Mercer E, Rekedal L, Garg R, et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther 2012;14:R135.
19. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis. Lupus 1996;5 Suppl 1(Suppl 1):16-22.
20. Suarez-Almazor ME, Belseck E, Shea B, et al. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000;4:CD000959.
21. Brunekreef T, Moens HB. OP0227 Remission induction with methotrexate step-up therapy versus combination of hydroxychloroquine, methotrexate and triamcinolone: 3 year results. Ann Rheum Dis 2017;76(Suppl 2):147-8.
22. Carmichael SJ, Beal J, Day RO, et al. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002;29:2077-83.
23. Panic N, Leoncini E, de Belvis G, et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-Analysis (PRISMA) statement on the quality of published systematic review and meta-Analyses. PLoS One 2013;8:e83138.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
25. Kerr G, Aujero M, Richards J, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res 2014;66:1619-26.
26. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010;37:1136-42.
27. Restrepo JF, Rincon del I, Molina E, et al. 2374 Use of hydroxychloroquine associated with improved lipid profile in rheumatoid arthritis patients. Arthritis Rheumatol 2014;66(S10):1033-4.
28. Rho YH, Oeser A, Chung CP, et al. Drugs used in the treatment of rheumatoid arthritis: Relationship between current use and cardiovascular risk factors. Arch Drug Inf 2009;2:34-40.
29. Bili A, Sartorius JA, Kirchner HL, et al. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011;17:115-20.
30. Holmqvist M, Wolfe F, Michaud K. FRI0117 D iabetes in rheumatoid arthritis: Incidence and association with RA treatment. Ann Rheum Dis 2013;71(Suppl 3):349.3-50.
31. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007;298:187-93.
32. Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: A randomized, blinded crossover trial. Arthritis Care Res 2014;66:1246-51.
33. Araiza-Casillas R, Díaz-Molina R, González-Ortiz M, et al. Effects of hydroxychloroquine on insulin sensitivity and lipid profile in patients with rheumatoid arthritis]. Rev Médica Chile 2013;141:1019-25.
34. Desai RJ, Eddings W, Liao KP, et al. Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: A retrospective cohort study. Arthritis Care Res 2015;67:457-66.
35. Bilecik NA, Tuna S, Samanci N, et al. Prevalence of metabolic syndrome in women with rheumatoid arthritis and effective factors. Int J Clin Exp Med 2014;7:2258-65.
36. Munro R, Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:374-7.
37. de Rotte MC, de Jong PH, den Boer E, et al. Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis. Arthritis Rheumatol 2014;66:2026-36.
38. Shapiro M, Levy Y. The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. Arthritis Rheumatol 2014;66(S10):812.
39. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: A case control study. Arthritis Res Ther 2006;8:R151.
40. Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine use Is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 2016;5:e002867.
41. Ozen G, Pedro S, Holmqvist ME, et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis 2017;76.
42. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-81.